A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

• Status: Terminated
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• Males and/or Females between 18-65 years, inclusive.

• Body mass index of 18.5 to 45.4 kg/m2 at screening, inclusive. body weight equals or greater than 110 lb.

• Have type 2 diabetes mellitus.

• On stable dose of anti-diabetic and anti-hypertensive medication prior to screening.

Exclusion Criteria:

• Recent evidence or medical history of unstable concurrent disease.

• Cardiovascular event within 3 months prior to screening.

• History of renal transplant.

• History of hospitalization for acute kidney injury or acute kidney dialysis within 6 months prior to screening.